Such multi-drug therapy was also postulated by Numakawa et al., who investigated the effect of flavonoids on neuroprotection and also noted that a promising direction in AD therapy is the inclusion of BDNF as a promising target for AD in combination with Aβ/tau-targeted therapy [118]. The gene discussed is MAPT; the disease is Alzheimer disease.